184 related articles for article (PubMed ID: 11890466)
1. Application of genetically altered models as replacement for the lifetime mouse bioassay in pharmaceutical development.
Alden C; Smith P; Morton D
Toxicol Pathol; 2002; 30(1):135-8. PubMed ID: 11890466
[TBL] [Abstract][Full Text] [Related]
2. The Tg rasH2 mouse in cancer hazard identification.
Morton D; Alden CL; Roth AJ; Usui T
Toxicol Pathol; 2002; 30(1):139-46. PubMed ID: 11890467
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the utility of the lifetime mouse bioassay in the identification of cancer hazards for humans.
Osimitz TG; Droege W; Boobis AR; Lake BG
Food Chem Toxicol; 2013 Oct; 60():550-62. PubMed ID: 23954551
[TBL] [Abstract][Full Text] [Related]
4. The Trp53 hemizygous mouse in pharmaceutical development: points to consider for pathologists.
Floyd E; Mann P; Long G; Ochoa R
Toxicol Pathol; 2002; 30(1):147-56. PubMed ID: 11890468
[TBL] [Abstract][Full Text] [Related]
5. Tg.AC genetically altered mouse: assay working group overview of available data.
Eastin WC; Mennear JH; Tennant RW; Stoll RE; Branstetter DG; Bucher JR; McCullough B; Binder RL; Spalding JW; Mahler JF
Toxicol Pathol; 2001; 29 Suppl():60-80. PubMed ID: 11695563
[TBL] [Abstract][Full Text] [Related]
6. A perspective on current and future uses of alternative models for carcinogenicity testing.
Goodman JI
Toxicol Pathol; 2001; 29 Suppl():173-6. PubMed ID: 11695554
[TBL] [Abstract][Full Text] [Related]
7. Alternative models for carcinogenicity testing: weight of evidence evaluations across models.
Cohen SM
Toxicol Pathol; 2001; 29 Suppl():183-90. PubMed ID: 11695556
[TBL] [Abstract][Full Text] [Related]
8. Mouse-specific carcinogens: an assessment of hazard and significance for validation of short-term carcinogenicity bioassays in transgenic mice.
Battershill JM; Fielder RJ
Hum Exp Toxicol; 1998 Apr; 17(4):193-205. PubMed ID: 9617631
[TBL] [Abstract][Full Text] [Related]
9. The role of transgenic mouse models in carcinogen identification.
Pritchard JB; French JE; Davis BJ; Haseman JK
Environ Health Perspect; 2003 Apr; 111(4):444-54. PubMed ID: 12676597
[TBL] [Abstract][Full Text] [Related]
10. Alternative models for carcinogenicity testing.
Cohen SM; Robinson D; MacDonald J
Toxicol Sci; 2001 Nov; 64(1):14-9. PubMed ID: 11606797
[TBL] [Abstract][Full Text] [Related]
11. Oxymetholone: II. Evaluation in the Tg-AC transgenic mouse model for detection of carcinogens.
Holden HE; Stoll RE; Blanchard KT
Toxicol Pathol; 1999; 27(5):507-12. PubMed ID: 10528629
[TBL] [Abstract][Full Text] [Related]
12. Neonatal mouse assay for tumorigenicity: alternative to the chronic rodent bioassay.
Flammang TJ; Tungeln LS; Kadlubar FF; Fu PP
Regul Toxicol Pharmacol; 1997 Oct; 26(2):230-40. PubMed ID: 9356286
[TBL] [Abstract][Full Text] [Related]
13. Alternatives to the 2-species bioassay for the identification of potential human carcinogens.
Ashby J
Hum Exp Toxicol; 1996 Mar; 15(3):183-202. PubMed ID: 8839204
[TBL] [Abstract][Full Text] [Related]
14. Tg.rasH2 Mouse Model for Assessing Carcinogenic Potential of Pharmaceuticals: Industry Survey of Current Practices.
Bogdanffy MS; Lesniak J; Mangipudy R; Sistare FD; Colman K; Garcia-Tapia D; Monticello T; Blanset D
Int J Toxicol; 2020; 39(3):198-206. PubMed ID: 32372678
[TBL] [Abstract][Full Text] [Related]
15. The National Toxicology Program evaluation of genetically altered mice as predictive models for identifying carcinogens.
Eastin WC; Haseman JK; Mahler JF; Bucher JR
Toxicol Pathol; 1998; 26(4):461-73. PubMed ID: 9715504
[TBL] [Abstract][Full Text] [Related]
16. CB6F1-rasH2 mouse: overview of available data.
Usui T; Mutai M; Hisada S; Takoaka M; Soper KA; McCullough B; Alden C
Toxicol Pathol; 2001; 29 Suppl():90-108. PubMed ID: 11695565
[TBL] [Abstract][Full Text] [Related]
17. In vivo transgenic bioassays and assessment of the carcinogenic potential of pharmaceuticals.
Contrera JF; DeGeorge JJ
Environ Health Perspect; 1998 Feb; 106 Suppl 1(Suppl 1):71-80. PubMed ID: 9539006
[TBL] [Abstract][Full Text] [Related]
18. An industry perspective on the utility of short-term carcinogenicity testing in transgenic mice in pharmaceutical development.
Storer RD; Sistare FD; Reddy MV; DeGeorge JJ
Toxicol Pathol; 2010 Jan; 38(1):51-61. PubMed ID: 19893055
[TBL] [Abstract][Full Text] [Related]
19. An analysis of pharmaceutical experience with decades of rat carcinogenicity testing: support for a proposal to modify current regulatory guidelines.
Sistare FD; Morton D; Alden C; Christensen J; Keller D; Jonghe SD; Storer RD; Reddy MV; Kraynak A; Trela B; Bienvenu JG; Bjurström S; Bosmans V; Brewster D; Colman K; Dominick M; Evans J; Hailey JR; Kinter L; Liu M; Mahrt C; Marien D; Myer J; Perry R; Potenta D; Roth A; Sherratt P; Singer T; Slim R; Soper K; Fransson-Steen R; Stoltz J; Turner O; Turnquist S; van Heerden M; Woicke J; DeGeorge JJ
Toxicol Pathol; 2011 Jun; 39(4):716-44. PubMed ID: 21666103
[TBL] [Abstract][Full Text] [Related]
20. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
Gaylor DW
Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]